Imunon Inc(IMNN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.84 | Insider Own | 14.29% | Shs Outstand | 5.6M | Perf Week | -26.32% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 22.95% | Insider Trans | -2.71% | Shs Float | 4.8M | Perf Month | -31.06% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.55 | Inst Own | 5.68% | Short Float | 1.3% | Perf Quarter | -42.41% |
| Income | -0.01B | P/S | - | EPS this Y | 65.42% | Inst Trans | -6.65% | Short Ratio | 0.53 | Perf Half Y | -67.5% |
| Sales | 0.00B | P/B | 1.01 | EPS next 5Y | 41.53% | ROA | -123.77% | Short Interest | 0.06M | Perf YTD | -76.12% |
| Book/sh | 0.9 | P/C | 0.74 | EPS past 3/5Y | 52.95% 44.66% | ROE | -429.72% | 52W High | -81% ($4.79) | Perf Year | -79.73% |
| Cash/sh | 1.22 | P/FCF | - | Sales past 3/5Y | - | ROIC | -145.66% | 52W Low | 12.33% ($0.81) | Perf 3Y | -93.02% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 71.67% | Gross Margin | - | Volatility(W/M) | 12.52% 9.56% | Perf 5Y | -99.49% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.11 | Perf 10Y | -99.97% |
| Dividend Ex-Date | - | Quick Ratio | 1.82 | EPS Q/Q | 71% | Profit Margin | - | RSI (14) | 36.04 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.82 | Sales Q/Q | - | SMA20 | -14.37% ($1.06) | Beta | 2.06 | Target Price | $17 |
| Payout | - | Debt/Eq | 1.87 | Earnings | 2026/8/11 | SMA50 | -30.71% ($1.31) | Rel Volume | 1.14 | Prev Close | $0.83 |
| Employees | 20 | LT Debt/Eq | 1.41 | EPS/Sales Surpr. | 37.75% - | SMA200 | -59.29% ($2.24) | Avg Volume(3M) | 0.12M | Price | $0.91 |
| IPO | 1994/4/4 | Option/Short | No/No | Trades | 287 | Volume | 132,520 | Change | 9.24% |
🧬 The company is a clinical-stage developer of immuno-oncology and gene-based therapies, built on its proprietary TheraPlas® platform, which combines DNA plasmids with nanoparticle delivery systems. Its lead candidate, IMNN-001 (an IL-12 DNA plasmid), is being advanced for ovarian cancer treatment in the Phase 3 OVATION-3 trial. In parallel, the company is also developing PlaCCine®, a DNA vaccine platform targeting infectious diseases.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded about as much as usual. That is 114% of its average volume.
IMNN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +65.4% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #543 of 597 in the industry
Based on market cap of $5M.
FAQ
What kind of company is IMNN?
IMNN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMNN?
The market cap of IMNN is approximately $5M, ranking 5,617 within its sector.
What is the 52-week high and low for IMNN?
IMNN has recorded a 52-week high of $4.79 and a low of $0.81.
